Toxicology

#Analysis #Automation / robotics #Business #Clinical trials #Drug development #Drug discovery #Enabling technologies #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Lead discovery #Preclinical #Regulatory #RNA #Screening #Therapeutics #Toxicology

Early Validation: The difference between success and failure?

Early Validation: The difference between success and failure? By Mike Benevento and Victor Bornsztejn Validation is typically associated with drug production and manufacturing, and often considered not to impact drug discovery and development. In fact, this assumption is not true and despite the fact that early-stage research may not require… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Target validation #Therapeutics #Toxicology

Restructuring Proteomics to Enable Personalised Cancer Care

Restructuring Proteomics to Enable Personalised Cancer Care By Dr Henry Rodriguez The genomics community has made great strides in our understanding of the molecular basis of cancer and these advances are slowly beginning to change the way we diagnose and treat patients. But genomic studies alone cannot capture the complete… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Organic chemistry #PCR #RNA #Screening #System biology #Systems biology #Toxicology

Letting the Target Determine your Compound Acquisition Strategy

Letting the Target Determine your Compound Acquisition Strategy By Dr John Harris With compound libraries likely to remain the cornerstone of hit and lead discovery for the foreseeable future, this paper seeks to summarise current and future approaches to optimal library design and compound acquisition, using examples and experimental evidence… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Drug targets #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Pathology #PCR #Pharmacology #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

High Throughput Screening, High Content Screening, Primary and Stem Cells

High Throughput Screening, High Content Screening, Primary and Stem Cells By Dr Richard M. Eglen Over the past decade, the use of cell-based assays has accelerated in modern drug discovery. Indeed, the majority of assays in either target validation or lead identification/optimisation all now employ cell-based technologies. Furthermore, a wide… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Animal models #Business #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Lead discovery #Lead optimisation #Oncology #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Toxicology

Predicting Transporter-mediated Drug-drug Interactions Based on in Vitro Cell Permeability Assays

Predicting Transporter-mediated Drug-drug Interactions Based on in Vitro Cell Permeability Assays By Dr Chris Bode Drugs may fail in clinical development or post-marketing for a variety of reasons: they may simply not be as effective as anticipated; poor pharmacokinetic properties may prevent them from reaching their intended target in therapeutic… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Molecular medicine #PCR #Pharmacology #Pharmokinetics #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Livening up HCS Imaging

Livening up HCS Imaging By Dr John Comley With the aid of recent end-user feedback, this article investigates interest in and use of live cell and kinetic HCS imaging; most wanted application areas: advantages of live cell HCS imaging; live cell HCS assays of greatest interest; what's limiting live cell… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Bioengineering #Business #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Organic chemistry #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Sequencing #System biology #Target validation #Toxicology

Natural Product Pharmaceuticals – The third generation

Natural Product Pharmaceuticals - The third generation By Dr Melanie McCullagh Compounds derived from natural products have made a big impact on the pharmaceutical industry. Of the 1,010 NCEs approved between January 1981 and June 2006, 43 were unaltered natural products (NPs) and a further 232 (23%) were second generation… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Flow Cytometry #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Metabolomics #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

High Content Screening – The next challenge: effective data mining and exploration

High Content Screening - The next challenge: effective data mining and exploration By Dr Kurt Zingler and Dr Stephan Heyse The use of high content screening within HTS is growing and with many past hurdles now overcome, the need for effective tools for data analysis is becoming paramount. Over the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biochemistry #Biomarkers #Business #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Lead discovery #Oncology #Pathology #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #RNA #Toxicology

Biomarker Signal Definition

Biomarker Signal Definition By Dr Gordon F. Kapke and Dr Nigel Brown Due to the numerous challenges in the industry, pharmaceutical companies are examining all aspects of the drug development process and rebuilding their associated business models as necessary. Companies need to improve success in late stage development, but what… Read More

#Archive

#Academic #Animal models #Business #Cell culture #Cell therapy #Cellular assays #Clinical trials #Drug development #Drug discovery #High Content Screening #Immunology #Molecular medicine #Pathology #Pharmacology #Preclinical #RNA #Screening #Stem cells #Toxicology

The Potential of High-resolution Human Immune Cell Assays to Aid the Pre-clinical to Clinical Transition of Drug Development Projects

The Potential of High-resolution Human Immune Cell Assays to Aid the Pre-clinical to Clinical Transition of Drug Development Projects By Dr Catherine A. Brady The effort to develop drugs that interact with the human immune system (whether by accident or design) has been dogged by a mismatch between the data… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Lead optimisation #PCR #Regulatory #RNA #Sequencing #Stem cells #Target validation #Toxicology

qPCR Assays – End user practices and latest vendor offerings

qPCR Assays - End user practices and latest vendor offerings By Dr John Comley This review provides an insight into real-time quantitative PCR (qPCR) assays today. Using end-user feedback it investigates interest in the targets for qPCR applications; primary application areas for qPCR analyses; the importance of emerging applications; how… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Clinical specialities #Clinical trials #Gene therapy #Pathology #Regulatory #RNA #Therapeutics #Toxicology

A Bronchoscopically Administered Therapeutic Approach to Advanced Emphysema

A Bronchoscopically Administered Therapeutic Approach to Advanced Emphysema By Dr Edward E. Berger Emphysema is a progressive, debilitating disease that affects approximately 4.1 million people in the United States or roughly 1% of the US population. The disease is characterised by destruction of lung tissue as a result of inflammation… Read More

#Archive

#Automation / robotics #Biochemistry #Biologics / Biotechnology #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Immunology #Oncology #Pathology #Preclinical #RNA #Target validation #Toxicology #Translational #Translational chemistry

Treating Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics

Treating Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics By Dr William E. Fogler Successful treatment paradigms for newly diagnosed rheumatoid arthritis (RA) now rely on aggressive pharmacotherapy approaches with disease-modifying antirheumatic drugs (DMARDs). Despite risks of toxicity and adverse effects, combination strategies with DMARDs are finding greater clinical… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Patent Law #PCR #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

High Throughput Screening in Academia – Drug discovery initiatives at the University of Kansas

High Throughput Screening in Academia - Drug discovery initiatives at the University of Kansas By Dr P McDonald, Dr Roy, Byron Taylor, Ashleigh Price, Dr Sittampalam, Dr Scott Weir, Dr Chaguturu Academia has historically been involved in exploring the fundamental aspects of the disease targets and in developing tool molecules… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene therapy #Genomics #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Precision medicine #Preclinical #Regulatory #RNA #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Next Generation Immunoassay Systems and the Revival of Protein Biomarkers

Next Generation Immunoassay Systems and the Revival of Protein Biomarkers By Dr John Todd and Dr Sara J. Agee Proteins are the machinery that drive most biological processes; however, measuring their concentrations at low levels has been historically impeded by a lack of appropriately sensitive technology. Advances in immunoassay technology,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cellular assays #Drug development #High throughput screening #Immunology #Pharmacology #Preclinical #Regulatory #RNA #Screening #Therapeutics #Toxicology

Challenges in Transferring Bioanalytical Methods

Challenges in Transferring Bioanalytical Methods By Dr Chris Beaver Drug development is arduous and expensive with any delay to market resulting in significant financial impact. Delays at any stage of the process cause challenges to programmes, however, some are easier to predict and plan for than others. Development of bioanalytical… Read More

#Archive